B cells and tertiary lymphoid structures influence survival in lung cancer patients with resectable tumors
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Tang, Jun
- dc.contributor.author Ramis Cabrer, Daniel, 1993-
- dc.contributor.author Curull Serrano, Víctor
- dc.contributor.author Wang, Xuejie
- dc.contributor.author Mateu Jiménez, Mercè, 1990-
- dc.contributor.author Pijuan Andujar, Lara
- dc.contributor.author Duran, Xavier
- dc.contributor.author Qin, Liyun
- dc.contributor.author Rodríguez-Fuster, Alberto
- dc.contributor.author Aguiló Espases, Rafael
- dc.contributor.author Barreiro Portela, Esther
- dc.date.accessioned 2021-04-07T05:51:24Z
- dc.date.available 2021-04-07T05:51:24Z
- dc.date.issued 2020
- dc.description.abstract Immune profile of B and T cells and tertiary lymphoid structures (TLSs) may differ in tumors of lung cancer (LC) patients with/without chronic obstructive pulmonary disease (COPD), and may also influence patient survival. We sought to analyze: (1) TLSs, germinal centers (GCs), B and T cells, and (2) associations of the immune biomarkers with the patients' 10-year overall survival (OS). TLSs (numbers and area), B [cluster of differentiation (CD) 20], and T (CD3), and GCs cells were identified in both tumor and non-tumor specimens (thoracotomy) from 90 LC-COPD patients and 43 LC-only patients. Ten-year OS was analyzed in the patients. Immune profile in tumors of LC-COPD versus LC: TLS numbers and areas significantly decreased in tumors of LC-COPD compared to LC patients. No significant differences were observed in tumors between LC-COPD and LC patients for B or T cells. Immune profile in tumors versus non-tumor specimens: TLS areas and B cells significantly increased, T cells significantly decreased in tumors of both LC and LC-COPD patients. Survival: in LC-COPD patients: greater area of TLSs and proportion of B cells were associated with longer survival rates. The immune tumor microenvironment differs in patients with underlying COPD and these different phenotypes may eventually impact the response to immunotherapy in patients with LC.
- dc.format.mimetype application/pdf
- dc.identifier.citation Tang J, Ramis-Cabrer D, Curull V, Wang X, Mateu-Jiménez M, Pijuan L, Duran X, Qin L, Rodríguez-Fuster A, Aguiló R, Barreiro E. B cells and tertiary lymphoid structures influence survival in lung cancer patients with resectable tumors. Cancers (Basel). 2020; 12(9):2644. DOI: 10.3390/cancers12092644
- dc.identifier.doi http://dx.doi.org/10.3390/cancers12092644
- dc.identifier.issn 2072-6694
- dc.identifier.uri http://hdl.handle.net/10230/47024
- dc.language.iso eng
- dc.publisher MDPI
- dc.relation.ispartof Cancers (Basel). 2020; 12(9):2644
- dc.rights © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.rights.uri http://creativecommons.org/licenses/by/4.0/
- dc.subject.keyword B cells
- dc.subject.keyword Chronic respiratory diseases
- dc.subject.keyword Lung cancer
- dc.subject.keyword Overall survival
- dc.subject.keyword Tertiary lymphoid structures
- dc.title B cells and tertiary lymphoid structures influence survival in lung cancer patients with resectable tumors
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/publishedVersion